In NAFLD, PCSK9 contributes to hepatic steatosis through receptor-dependent and -independent pathways, upregulating genes associated with lipid synthesis and cholesterol biosynthesis [36]. The gene discussed is PCSK9; the disease is metabolic dysfunction-associated steatotic liver disease.